GlassScriptPhysician profile
Karla Rugamas
NPI 1912247149
$5,810.50
in general payments reported to CMS, 2019-2025
29 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,607 · 2022: $529 · 2023: $1,174 · 2024: $1,152 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,674.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $908.66 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $620.45 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $507.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $504.43 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $458.96 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Glaxosmithkline, LLC. | $422.20 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $340.36 | 2021-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $295.59 | 2021-2024 | Trintellix |
| Radius Health, INC. | $294.85 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.77 | 2021-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $182.94 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Esperion Therapeutics, INC. | $164.91 | 2021 | |
| Astellas Pharma US INC | $132.32 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $125.01 | 2021-2023 | Austedo |
| Novartis Pharmaceuticals Corporation | $112.99 | 2021-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $90.86 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $81.63 | 2023-2024 | Ingrezza |
| Sanofi-Aventis U.S. LLC | $54.76 | 2021-2022 | |
| Pfizer INC. | $34.59 | 2021 | |
| Corcept Therapeutics | $34.47 | 2025 | Korlym |
| Viiv Healthcare Company | $29.00 | 2025 | Apretude |
| Amarin Pharma, INC. | $23.59 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.37 | 2023 | Gvoke Hypopen |
| Abbott Laboratories | $21.48 | 2021 | |
| Ironwood Pharmaceuticals, INC | $20.87 | 2021 | |
| Lundbeck LLC | $17.60 | 2024 | Rexulti |
| Exact Sciences Corporation | $16.43 | 2025 | The Cologuard Plus Collection Kit |
| Arbor Pharmaceuticals, INC. | $15.77 | 2021 | |
| Nestle Healthcare Nutrition INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Rugamas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.